Vancouver, BC & Scottsdale, AZ - November 9, 2026 – Vesalius Longevity Labs Inc. (formerly Sweet Earth Holdings Corporation) (“Vesalius” or the “Company”) (CSE: SE) (to trade as “VLAB”), a leading global peptide and longevity company today announced that it has completed a non-brokered private placement (the “Offering”) of 6,190,475 units of the Company (each a “Unit”) at a price of US$1.05 per Unit, for aggregate gross proceeds of US$6,499,998.75.
The strategic financing was led by a group organized by Harvey Spevak, an investor and visionary leader in global wellness, lifestyle and hospitality, and Chairman of Equinox Group. With more than three decades of experience building and scaling distinctive consumer brands, Mr. Spevak is recognized for his brand-focused, consumer-centric approach to innovation, growth and long-term value creation.
The financing led by the investor group organized by Mr. Spevak marks a significant milestone for Vesalius as the Company scales its global longevity platform. Mr. Spevak’s backing is a strong vote of confidence in Vesalius’s vision to close the gap between longevity science and clinical practice. It also validates the Company’s prescriber-led, quality-first model, which connects licensed healthcare providers with peptide therapeutics globally. With this injection of capital, Vesalius is well positioned to expand its sales team, enter new markets and help meet growing demand for safe, regulated access to longevity therapies.
“I believe longevity represents one of the most exciting opportunities in health and wellness over the coming decade,” said Harvey Spevak. “Vesalius has an ambitious vision for building a differentiated platform. I’m excited to partner with the team and bring my experience in building consumer-focused brands, driving innovation and creating long-term value to help shape the company’s next phase of growth.”
Each Unit consists of one common share in the capital of the Company (each a “Company Share”) and one-half of one Company Share purchase warrant (each whole warrant a “Warrant”), with each whole Warrant exercisable to acquire one additional Company Share at a price of USD$2.25 for a period of two years from the closing date. The Warrants are subject to an acceleration right in favor of the Company, which may be exercised by written notice to Warrant holders if the volume-weighted average trading price of the common shares on a recognized stock exchange is at or above CAD$3.50 for any twenty consecutive trading days, in which case the expiry date of the Warrants will be accelerated to a date not less than sixty days following the date of such notice.
The securities issued pursuant to the Offering are subject to a statutory hold period of four (4) months plus a day from the date of issuance in accordance with applicable securities legislation.
About Vesalius
Vesalius Longevity Labs is a longevity science and regenerative health platform focused on peptides, biologics, preventative healthcare and performance optimization. Vesalius operates a scalable B2Doctor2Consumer ecosystem designed to support healthcare providers, telehealth infrastructure, product fulfillment and advanced longevity therapeutics across global markets. Vesalius’s expanding ecosystem includes peptide therapeutics, regenerative medicine initiatives, royalty-generating biologics partnerships and advanced provider enablement technologies designed to support the future of personalized health and wellness.
For more information, visit: https://www.vesaliuslabs.com/
For further information, please refer to the Company’s disclosure record on SEDAR+ at www.sedarplus.ca.
Company Contact
Julia Becker Vice President, Capital Markets +1(604)785-0850 jbecker@vesaliuslabs.com
Media Contact: vesalius@jacktaylorpr.com